Author

D. M. Fines

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

E. Van Dis· 2 shared J. S. Cox· 2 shared S. A. Stanley· 2 shared A. Anaya-Sanchez· 1 shared A. W. Roberts· 1 shared C. C. Ward· 1 shared C. Dugast-Darzacq· 1 shared D. Dovala· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

E. Van Dis

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Mycobacterial formation of intracellular lipid inclusions is a dynamic process associated with rapid replication

D. M. Fines, D. Schichnes, M. Knight, A. Anaya-Sanchez, N. T. T. Thuong, J. S. Cox, S. Stanley

This study shows that mycobacteria form intracellular lipid inclusions during active replication without environmental stressors, challenging the link between ILI and non-replicating persistence.

bioRxiv · Aug 10, 2023 · PreprintMicrobiology

IFN-γ-independent control of M. tuberculosis requires CD4 T cell-derived GM-CSF and activation of HIF-1α

E. Van Dis, H. M. Morrison, D. M. Fines, J. P. Babirye, L. H. McCann, S. Rawal, J. S. Cox, S. A. Stanley

This study identifies GM-CSF and HIF-1 activation as IFN-γ-independent mechanisms by which CD4 T cells control M. tuberculosis infection.

bioRxiv · Dec 16, 2021Immunology

Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2

S. B. Biering, E. Van Dis, E. Wehri, L. H. Yamashiro, X. Nguyenla, C. Dugast-Darzacq, T. G. Graham, J. R. Stroumza, G. R. Golovkine, A. W. Roberts, D. M. Fines, J. N. Spradlin, C. C. Ward, T. Bajaj, D. Dovala, , S. A. Stanley

This study screens FDA-approved compounds for antiviral activity against SARS-CoV-2 and identifies 13 effective compounds, including seven new candidates and one synergistic combination with remdesivir.

bioRxiv · Dec 30, 2020Microbiology